Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Voyager Therapeut (VYGR)

Voyager Therapeut (VYGR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Voyager Therapeutics: Q2 Earnings Snapshot AP - Thu Aug 6, 3:44PM CDT

Voyager Therapeutics: Q2 Earnings Snapshot

VYGR : 3.20 (unch)
Voyager Reports Second Quarter 2026 Financial and Operating Results GlobeNewswire - Thu Aug 6, 3:01PM CDT

- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 - - Ended Q2 2026 with cash position of $149 million, runway into 2028 - LEXINGTON, Mass., Aug. 06, 2026...

VYGR : 3.20 (unch)
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 GlobeNewswire - Mon Jul 13, 7:01AM CDT

- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging...

VYGR : 3.20 (unch)
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 GlobeNewswire - Mon Jun 29, 7:01AM CDT

LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced...

VYGR : 3.20 (unch)
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference GlobeNewswire - Thu Jun 11, 3:01PM CDT

LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced...

VYGR : 3.20 (unch)
Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease GlobeNewswire - Mon Jun 1, 7:00AM CDT

- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 - - VY1706...

VYGR : 3.20 (unch)
Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026 GlobeNewswire - Wed May 13, 5:01AM CDT

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager’s continued innovation in gene therapy - LEXINGTON,...

VYGR : 3.20 (unch)
Voyager Therapeutics: Q1 Earnings Snapshot AP - Thu May 7, 3:40PM CDT

Voyager Therapeutics: Q1 Earnings Snapshot

VYGR : 3.20 (unch)
Voyager Reports First Quarter 2026 Financial and Operating Results GlobeNewswire - Thu May 7, 3:01PM CDT

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month GLP tox data - ...

VYGR : 3.20 (unch)
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease GlobeNewswire - Mon Apr 27, 3:31PM CDT

- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs - - Additional...

VYGR : 3.20 (unch)

Barchart Exclusives

Target Appoints Its First-Ever AI Exec as the Retailer Pushes Deeper Into Artificial Intelligence. What It Means for TGT Stock. Barchart - Wed Aug 12, 6:30PM CDT
Target appointed Chandhu Nair as its first chief artificial intelligence officer, effective Aug. 24, as the retailer expands its use of AI across inventory, operations, and customer experience. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.